[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Université de Montréal\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":211},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,73,107,133,159,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100612884","neuro-inflammation-in-extremity-trauma-risk-verification-in-elbow-trauma-the-nerve-study-100612884",false,"NCT07259382","Neuro-Inflammation in Extremity Trauma: Risk Verification in Elbow Trauma: The NERVE Study","Neuro-Inflammation in Extremity Trauma: Risk Verification in Elbow Trauma: The NERVE Pilot Cohort Study","NERVE","Inclusion Criteria:\n\n* Adults 18 years or older with an acute elbow fracture and\u002For dislocation less than a week old\n* Open surgery as the chosen treatment\n\nExclusion Criteria:\n\n* Patient with a history of ipsilateral upper limb trauma or pathology, neurological disorder.\n* Patient unable to answer questionnaires.\n* Patient unavailable for a one-year follow-up, for example from another country.\n* Patient with vascular injury or open fracture\n* Patient with an active inflammatory disease (ex: rheumatoid arthritis)\n* Patient using anti-inflammatory drugs or immunosuppressants at the time of the injury.\n* Patient with another acute ipsilateral injury to the upper limb\n* Polytrauma patients with other injuries than the elbow fracture and concomitant central or peripheral neurological injury.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","The primary goal of this proposal is to improve the understanding of the mechanisms causing persistent pain and disability in elbow fracture patients and their associated functional limitations. The specific objectives are as follows for elbow fractures:\n\n1\\) To describe NI mechanisms using biomarkers; 2) To identify factors related to increased NI biomarkers level; 3) To describe the associations between NI and outcomes; 4) To use these findings to refine a larger fully powered prognostic cohort study Hypotheses\n\n1. Level of neuro-inflammation (NI) biomarkers\\* will be significantly higher in patients presenting with both elbow fracture and CNS injury or PNI.\n2. Consumption of opioid in mg of morphine equivalent will be higher in patients with a higher level of NI biomarkers.\n3. Function, assessed by validated joint and limb specific functional questionnaires and QoL will be worse in patients with a higher level of NI biomarkers.\n4. Chronic pain at 3 months will be higher (McGill Pain questionnaire V2, Neuropathic pain questionnaire, NPRS) in patients with a higher level of NI biomarkers.\n5. Duration of tourniquet use and nerve dissection will be correlated to elbow fracture outcome with a higher level of NI biomarkers.\n\n   * Target biomarkers based on preliminary study will include, but not be limited to: TNFa, IL6, Substance P, IL-1B, TREM-2, IL-16, CCL22, VEGF-a, BMPs (table 1).",[25,26,27,28,29],"Elbow Dislocation","Elbow Fractures","Inflammation Biomarkers","TBI Traumatic Brain Injury","Nerve Injury",[31,32,33,34,35],"Biomarkers","Elbow fracture","elbow dislocation","Nerve injury","TBI","NOT_YET_RECRUITING","2026-04-27",{"date":39,"type":40},"2026-04-28","ACTUAL",{"date":42,"type":21},"2026-06-01",{"date":44,"type":21},"2030-12-31",{"name":46,"class":47},"Université de Montréal","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100285516","antimicrobial-prophylaxis-for-skin-colonization-with-propionibacterium-acnes-in-primary-open-shoulder-surgery-100285516","NCT02996656","Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery","Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery: A Double Blinded Randomized Controlled Trial","PAPA","Inclusion Criteria:\n\n* 18 years and older\n* Male or female\n* Presenting normal skin on the shoulder aria\n\nExclusion Criteria:\n\n* Used antibiotics or treated their skin with antibiotic gel, alcohol gel or cream or acne treatment in the last three months\n* Active infection at the surgical site or anywhere\n* Affected shoulder previously received radiotherapy\n* Allergic to one of the antimicrobial prophylaxis used\n* Open fracture\n* Life threatening or a limb threatening pathology\n* Liver or kidney failure",{"count":57,"type":21},88,"INTERVENTIONAL",[60],"NA","INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. With the increasing rate of identified P. acnes shoulder surgery infection despite the use of recommended skin preparation and preoperative prophylactic antibiotics, a question arises; Is Cefazolin the most effective prophylactic antibiotic for shoulder surgery? The objective of this study is to determine if Ceftriaxone is superior to Cefazolin as a prophylactic antibiotic for skin colonization with P. acnes in primary shoulder surgery",[63],"Propionibacterium Infection","RECRUITING",{"date":66,"type":40},"2026-05-01",{"date":68,"type":4},"2016-12",{"date":70,"type":21},"2026-12",{"name":46,"class":47},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":72},"100622916","maple-syrup-carbohydrate-dose-response-on-20-km-cycling-time-trial-performance-100622916","NCT07389837","Maple Syrup Carbohydrate Dose-Response on 20-km Cycling Time-Trial Performance","Dose-Response Effects of Maple Syrup Carbohydrate Ingestion (60, 90, 120 g\u002Fh) on 20-km Cycling Time-Trial Performance, Substrate Oxidation, and Perceptual Responses in Trained Male Cyclists","MAPLE-DR","Inclusion Criteria:\n\n* Age: 18-45 years.\n* Relative VO2max: \\>55 mL·min-¹·kg-¹ for level 3; \\>65 mL·min-¹·kg-¹ for level 4.\n* Peak Power Output (PPO): \\>4.6 W·kg-¹ (absolute PPO \\>320 W).\n* Training History: \\>5 hours\u002Fweek of cycling-specific training; \\>1 year of consistent endurance training.\n* No history of metabolic disorders, gastrointestinal issues, or contraindications to exercise testing.\n\nExclusion Criteria:\n\n* Current or past metabolic disorders (diabetes, metabolic syndrome)\n* Cardiovascular disease or abnormal ECG at rest\n* Gastrointestinal disorders (IBS, Crohn's, celiac disease)\n* Food allergies or intolerances (particularly maple, fructose)\n* Current use of medications affecting metabolism\n* Smoking or nicotine use\n* Alcohol consumption \\>14 units\u002Fweek\n* Recent illness or injury (\\\u003C4 weeks)\n* Participation in other clinical trials (\\\u003C3 months)\n* Unable to maintain consistent training during study period",true,"MALE","45 Years",{"count":85,"type":21},32,[60],"The goal of this clinical trial is to learn whether maple syrup can be used as a natural carbohydrate source to help trained male cyclists perform better during long-duration cycling. The study also aims to learn how different amounts of maple syrup affect energy use in the body, stomach comfort, and feelings of effort and fatigue.\n\nThe main questions the study aims to answer are:\n\n* Does consuming more carbohydrate from maple syrup help participants finish a 20-kilometer cycling time trial faster?\n* How do different amounts of maple syrup change how the body uses carbohydrates and fats during long exercise?\n* Are higher amounts of maple syrup easy for participants to tolerate without stomach problems?\n\nResearchers will compare four drinks:\n\n1. A placebo drink (a look-alike drink with no calories),\n2. A drink that provides 60 grams of carbohydrate per hour,\n3. A drink that provides 90 grams per hour, and\n4. A drink that provides 120 grams per hour.\n\nThey will compare these drinks to see whether higher carbohydrate amounts lead to better cycling performance and how each dose affects comfort and metabolism.\n\nParticipants will:\n\n* Attend a screening visit that includes a health check and a glucose tolerance test.\n* Complete a fitness test to measure their aerobic capacity and practice the cycling tests used in the study.\n* Take part in four separate exercise sessions in random order. Each session includes:\n* Drinking one of the four study beverages during 2 hours of steady cycling,\n* Completing two short, all-out 6-second sprints during the ride,\n* Completing a 20-kilometer cycling time trial as fast as possible,\n* Reporting stomach symptoms and perceptions of effort,\n* Providing breath, blood, urine, and sweat samples so researchers can measure how their body uses fuel.\n\nAll drinks will look, taste, and smell similar so participants cannot tell which one they are receiving. Meals before each session will be provided to keep conditions the same across visits.\n\nThis study may help athletes and active people choose natural carbohydrate sources that support both performance and comfort during long endurance exercise. The findings may also guide future research on the use of maple syrup as a sports nutrition option.",[89,90,91,92],"Exercise","Endurance Cycling Performance","Carbohydrate Intolerance","Sport Nutrition",[94,95,96,97,98],"13C-glucose","cycling exercise","endurance performance","carbohydrate","substrate oxidation","2026-01-28",{"date":101,"type":40},"2026-02-05",{"date":103,"type":21},"2026-02-01",{"date":105,"type":21},"2027-06-01",{"name":46,"class":47},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":58,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},"100607905","phase-4-pilot-and-feasibility-study-of-impact-of-sdf-38-application-on-oral-health-of-elderly-with-autonomy-loss-100607905","NCT07194629","Pilot and Feasibility Study of Impact of SDF 38% Application on Oral Health of Elderly With Autonomy Loss","Impact of Silver Diamine Fluoride (SDF) 38% Application on the Oral Health of the Elderly With Loss of Autonomy Living in Long-term Care Homes (CHSLDs): A Pilot and Feasibility Effectiveness Study","Inclusion Criteria:\n\n* Elderly of 65 years of age or older living at a long-term care facility targeted by the study.\n* Should present at least one coronal or radicular active carious lesion that is asymptomatic, untreated, or a residual lesion under a restoration, and without pulp involvement.\n\nExclusion Criteria:\n\n* Participants with inadequate collaboration that may impede dental examination or treatment.\n* Participants with cardiac valve prostheses, a history of bacterial endocarditis, or valve disease following a heart transplant.\n* Completely edentulous elderly, as well as elderly presenting with no coronal or radicular caries\n* Participants allergic to silver, fluoride or ammonia.","65 Years",{"count":20,"type":21},[117],"PHASE4","Introduction: Dental caries constitutes a major oral health problem at a global scale for the elderly population. It impacts the health system due to its high incidence and prevalence and its associated costs. The growing population of elderly experiencing a loss of autonomy is accompanied by a decline in motor functions, which affects their ability to carry out everyday tasks such as brushing their teeth. The resulting poor oral hygiene can contribute to the onset of oral diseases. Dental caries can significantly impact the quality of life of the elderly by provoking pain, chewing difficulties, tooth loss and malnutrition. Recently, Silver Diamine Fluoride (SDF) 38% has been introduced to the market as an efficient solution for promoting oral health and arresting active caries. SDF is a compound of silver, fluoride, and ammonia, which comes in the form of a bluish liquid and is applied in small amounts on active carious lesions. Despite its recent approval by Health Canada as a temporary solution for arresting active caries, few randomized controlled trials have evaluated its effectiveness on the institutionalized elderly.\n\nObjectives: This pilot study aims to evaluate the impact of SDF on the oral health of the elderly living in long-term care facilities.\n\nPrincipal objective: evaluate effectiveness of SDF on arrestation of active caries when applied for the elderly with loss of autonomy in long-term care facilities.\n\nSecondary objectives:\n\n1. evaluate the relationship between SDF application and caries activity\n2. Analysis of salivary biomarkers involved in the associated inflammatory processes.\n\nMethodology: A randomized controlled feasibility and effectiveness study design will be employed. This study will span over 12 months and will include 3 data collection phases.\n\nAt T0 (baseline): SDF group participants will receive an SDF application on their active caries. Control group participants will receive a 0.9% saline solution (placebo) application.\n\nAT T1, 6 months after T0: First phase of data collection, the two groups will receive SDF application.\n\nAt T2, 12 months after T0: second phase of data collection, and for ethical reasons, the control group, who received placebo at T0, will receive an SDF application.\n\nAt the end of the project, a fluoride varnish application will be carried out on both groups to prolong preventive effects of treatment. A short questionnaire will also be shared with participants to evaluate their satisfaction and identify unintended adverse effects.\n\nAnticipated results:\n\nDemonstrate the efficiency of SDF in controlling active caries in the elderly with autonomy loss.\n\nElaborate a clinical protocol for SDF application in long-term care facilities Establish the required sample size for a future bigger study.",[120,121,122,123],"Dental Caries","Elderly","Loss of Autonomy","Silver Diamine Fluoride","2025-09-18",{"date":126,"type":40},"2025-09-26",{"date":128,"type":21},"2025-10-01",{"date":130,"type":21},"2026-12-31",{"name":46,"class":47},3,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":58,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":72},"100350203","study-of-personalized-instrument-in-total-shoulder-arthroplasty-the-pitsa-study-100350203","NCT03839758","Study of Personalized Instrument in Total Shoulder Arthroplasty The P.I.T.S.A. Study","Multicenter Randomised Study of Personalized Instrument in Total Shoulder Arthroplasty The P.I.T.S.A. Study","PITSA","Inclusion Criteria:\n\n* Patients with shoulder osteaoarthritis and AVN\n\nExclusion Criteria:\n\n* Patients with previous shoulder arthroplasty\n* Patients with inflammatory arthritis and tumor\n* Patients with previous shoulder surgery with metal implant\n* Patients refusing 2-year follow-up\n* Patients that does not speak English or French\n* Patients with current or previous shoulder infection\n* Patients with graft during surgery","99 Years",{"count":143,"type":21},112,[60],"Total shoulder arthroplasty is an effective procedure to improve patients function and to relieve shoulder pain in cases of glenohumeral arthritis. The main challenge of this procedure is implanting the glenoid component. Indeed, surgical exposure is difficult and proper visualization of the glenoid is demanding. The current free-hand method is not precise and especially unreliable in glenoids with severe deformity. Inappropriate reaming and glenoid positioning can cause more bone loss during surgery.\n\nIn anatomic prostheses, glenoid component fixation is demanding and is the first component to present loosening at long term follow-up. When it comes to reverse arthroplasty, the glenoid component, once again, requires the most attention. Malpositioning of the glenosphere can cause notching, loosening, and instability.\n\nIn order to prevent these complications, precision in glenoid implantation is key. To this end, intraoperative computer navigation would be a helpful tool, but the increased expenses in computer equipment represent massive costs and possibly increases in surgical time. A more affordable option is a personalized guide, for which the only extra expense is the customized guide. These guides are based on precise 3D CT scan templates. Previous studies have evaluated the precision of the guide in vivo and in vitro, but none have measured it in a randomized study. As it represents additional costs, its efficacy needs to be proven before widespread use.\n\nThis method may also provide secondary benefits, such as decreasing operating time, lowering short- and long-term complications, and improving efficacy.\n\nThe objective of this study is to evaluate the performance of a patient specific glenoid guide.",[147],"Shoulder Arthritis",[149,150],"Prothesis","Glenoid implantation","2025-09-16",{"date":153,"type":40},"2025-09-22",{"date":155,"type":40},"2019-10-08",{"date":157,"type":21},"2028-12",{"name":46,"class":47},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":81,"sex":17,"minAge":167,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":58,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":132},"100594889","spotting-and-managing-adult-repeated-traumas-in-the-brain-100594889","NCT07025317","Spotting and Managing Adult Repeated Traumas in the Brain","Developing an Evidence-based Approach to Diagnose and Treat Adults With a History of Concussion","SMARTBRAIN","Inclusion Criteria:\n\n* It will be based on age (60+ years) and history of concussion (with the most recent concussion occurring at least one year prior to the study). Consistent with the literature, the history of concussion will be determined by interviewing participants about their experience with each experience of concussion (e.g. how was the injury sustained (sports injury, vehicle accident, etc.), how long has it been since the injury, did they experience a loss of consciousness during the event, how was their concussion diagnosed, what were their symptoms and when did the symptoms resolve).\n\nThe interview will also gather information on age, sex, gender, education, occupation, and medical history (e.g. mood, medications). These variables will be coded and included in analyses, as appropriate. For example, years of education and years since the most recent concussion can be used as covariates.\n\nExclusion Criteria:\n\n* Include the presence of a diagnosed neurological disorder (e.g. Mild Cognitive Impairment, Alzheimer's disease, Parkinson's disease), history of severe psychiatric disorder (e.g. schizophrenia), or any condition or medication that could affect cognition (e.g. psychotropic, anticholinergic drugs). Exclusion criteria also screen out the presence of any diagnosed visual impairment that could impede NeuroTracker training (i.e. severe colour blindness, monocular vision, blindness), and contraindications for MRI (e.g. metal implants).","60 Years",{"count":169,"type":21},200,[60],"Emerging evidence suggests that concussions (a type of mild traumatic brain injury; mTBIs) may cause chronic neurological disturbances with effects lasting beyond 20 years, changing brain structure and nearly doubling the risks of developing dementia into old age. Yet diagnoses remain notoriously difficult, gender differences are poorly understood, and negligible therapies exist to manage and treat these long-term effects.\n\nThis project proposes using a combination of NeuroTracker (a promising software-based cognitive assessment and intervention for mild TBIs), with the latest MRI techniques and blood-based biomarkers of brain function, to provide unprecedented assessment sensitivity of long-term concussion effects, comparing older male and female adults, with and without a history of concussion. Additionally, NeuroTracker will be used as a therapeutic intervention to improve outcomes in adults with histories of concussion, with the combined assessments measuring efficacy pre-post training.\n\nThis project aims to comprehensively understand the impacts of mild brain traumas into later life, via both physical and functional biomarkers of brain health. It will also validate the value of NeuroTracker as an accessible training intervention for recovering cognitive functions impacted by earlier-life concussions.",[173],"Brain Injury Traumatic Mild",[175,176,177,178],"Concussions","mild traumatic brain injury","mild brain traumas","NeuroTracker","2025-07-16",{"date":181,"type":40},"2025-07-20",{"date":183,"type":40},"2024-03-01",{"date":185,"type":21},"2027-02-28",{"name":46,"class":47},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":194,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":58,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":72},"100564829","comparison-of-two-reeducation-methods-in-children-with-persistent-sleep-apnea-a-randomized-controlled-trial-100564829","NCT06634264","Comparison of Two Reeducation Methods in Children With Persistent Sleep Apnea, a Randomized Controlled Trial","PERSIST-B-RCT","Inclusion Criteria:\n\nparticipants must:\n\n* present signs of obstructive sleep apnea: snoring, apnea \u002F respiratory pauses audible by the entourage (objectivized by a score, to the Pediatric Sleep Questionnaire (PSQ) , greater than or equal to 0.33- This questionnaire comprises twenty-two Questions and has a good sensitivity (83%) and specificity (87%) in screening for pediatric sleep apnea.\n* be programmed for adenoidectomy, tonsillectomy or adeno-tonsillectomy within 3 months (or more).\n\nExclusion Criteria:\n\nparticipants should not:\n\n* present with a craniofacial syndrome nor a severe medical condition with complex medical management,\n* present with an abnormality of the neuromuscular tone (such as Duchenne myopathy or cerebral palsy)\n* receive orthodontic therapy during the study\n* have a class III malocclusion (mandibular prognathy type), for which a propulsion oral appliance is contraindicated because it may aggravate mandibular prominence. Maxillary deficiency is not a exclusion criterion.\n* A non-nutritive oral habit such as digital sucking (or pacifier) that persists because it interferes with oral reeducation and is a contraindication to orthodontic treatments. Children who have recently stopped such a habit may be included in the study.","4 Years","14 Years",{"count":20,"type":21},[60],"Myofunctional therapy has been shown to be effectively reduce symptoms of paediatric obstructive sleep apnea, usually performed after adenotonsillectomy.\n\nThis study aims to evaluate the effectiveness of Passive Oral Myofunctional Reeducation (using a flexible oral appliance) compared to nasal hygiene alone (control group), in a population of children scheduled for adenotonsillectomy.",[200,201,202],"Obstructive Sleep Apnea of Child","Sleep-Disordered Breathing","Adenotonsillar Hypertrophy","2024-10-07",{"date":205,"type":40},"2024-10-09",{"date":207,"type":40},"2024-03-20",{"date":209,"type":21},"2027-03-31",{"name":46,"class":47},""]